Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System

doi:10.19803/j.1672-8629.2021.06.01

Abstract

Abstract: Objective To explore the significance of Good Pharmacovigilance Pracetice (GVP)in constructing the Pharmacovigilance System of China. Methods review the background of GVP, study its status in the field of drug safety supervision, summarize its core and gist, discuss its role in the Pharmacovigilance System, and analyze the significance of its introduction. Results and Conclusion the promulgation and implementation of GVP is the first step in the construction of China Pharmacovigilance System, which has great significance and far-reaching influence.

Key words: pharmacovigilance, pharmacovigilance system, adverse drug reaction monitoring, good pharmacovigilance practice

CLC Number:

R951

WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le. Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.

References

[1] NMPA.NMPA announcement on issuing good pharmacovigilance practices (No.65 of2021)[EB/OL].(2021-05-13)[2021-05-13]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[2] Yuan L, Zhang GT, Sun Q.The history and significance of China's entry into ICH[J]. China Food & Drug Admi-nistration Magazine(中国食品药品监管), 2018, 176(9): 4-20.
[3] SFDA. SFDA announcement on application of the secondary guidelines of ICH (No. 10, 2018) [EB/OL].(2018-01-25)[2021-04-13]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20180125175101686.html.
[4] NMPA. NMPA announcement on application of ICH guideline E2C(R2): periodic benefit-risk evaluation report (PBRER) (No. 86, 2020)[EB/OL].( 2020-07-17)[2021-04-13]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200721172101743.html.
[5] CDE. CDE announcement on issuing the good practice of Develo-pment Safety Update Report (Trial)(2020.No.7) [EB/OL].( 2020-07-01)[2021-04-13]. http://www.cde.org.cn/news.do?method=largeInfo&id=3cad3925b893ab31.
[6] NMPA.NMPA announcement on direct reporting of adverse reactions by drug marketing authorization holders (No. 66, 2018) [EB/OL]. (2018-09-30)[2021-04-13]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180930174301286.html.
[7] Standing Committee of the National People's Congress. Drug Admin-istration Law of the People's Republic of China[EB/OL].(2019-08-26)[2021-04-13]. http://www.gov.cn/xinwen/ 2019-08/26/content_5424780.htm.
[8] Dong D, Wu GZ, Cheng G.Introduction of european union pharmacovigilance system facing new regulation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒). 2012, 9(11): 662-665.
[9] MOH. Regulations for the administration of adverse drug reaction reporting and monitoring (No.81, 2011)[EB/OL].(2011-05-04)[2021-04-13].https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.html.
[10] NMPA. Measures for the supervision and administration of drug production[EB/OL].(2019-08-26)[2021-04-13]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/20171121171401897.html.

[1]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[2]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[3]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[4]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[5]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[9]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[10]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[11]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[12]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[13]	WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong. Current applications of artificial intelligence in pharmacovigilance in the USA and implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
[14]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
[15]	JIANG Hao, ZHANG Bing, ZHANG Xiaomeng, LIN Zhijian, LYU Jintao, ZHANG Dan. Descriptions of pharmacovigilance in materia medica works of Sui, Tang and the Five Dynasties [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 987-993.